Shopping Cart
- Remove All
Your shopping cart is currently empty
HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $91 | 35 days | |
| 5 mg | $319 | 35 days | |
| 10 mg | $543 | 35 days | |
| 50 mg | $1,980 | 35 days |
| Description | HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma. |
| Synonyms | PP21 |
| Molecular Weight | 394.85 |
| Formula | C22H19ClN2O3 |
| Cas No. | 2454582-64-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Methanol: Soluble Ethanol: Soluble Chloroform: Soluble Acetonitrile: Soluble |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.